Alinidine in angina

Publisher Website
Google Scholar
Abstract
Alinidine-N-allyl-clonidine-reduces heart rate without blocking .beta.-adrenoreceptors. It may be used in patients with angina without inducing the adverse effects of .beta.-adrenergic blockers. Alinidine efficacy was evaluated in patients with angiographically proven coronary artery disease and stable angina during a 10-wk placebo-controlled randomized double-blind trial. Alinidine (40 mg 3 times a day) reduced the number of anginal attacks and the average number of nitroglycerin capsules consumed. The double product was slightly lowered during rest but more pronounced during exercise. This effect was mainly due to decreased heart rate. The ischemic S-T segment depression was diminished. Exercise tolerance was clearly improved in 6, slightly improved in 2 and unchanged in 4 subjects.

This publication has 0 references indexed in Scilit: